Sign In

Login

Password

Forgot Password ? Sign Up

GBP510 (Czech Wikipedia)

Analysis of information sources in references of the Wikipedia article "GBP510" in Czech language version.

refsWebsite
Global rank Czech rank
3clinicaltrials.gov
5,225th place
2,661st place
2businesskorea.co.kr
low place
low place
2uw.edu
low place
9,950th place
1skbioscience.co.kr
low place
low place
1cepi.net
low place
low place
1bioworld.com
low place
low place

bioworld.com

  • SK Bioscience advances first South Korean-developed COVID-19 vaccine to late-stage testing. www.bioworld.com [online]. [cit. 2021-11-16]. Dostupné online. (anglicky) 

businesskorea.co.kr

  • SK Bioscience's COVID-19 Vaccine Uses Nanoparticle Technology of University of Washington. Businesskorea [online]. 2021-06-11 [cit. 2021-11-16]. Dostupné online. (korejsky) 
  • SK Bioscience Starts to Administer COVID-19 Vaccines to Subjects in Phase 3 Trial. Businesskorea [online]. 2021-08-31 [cit. 2021-11-16]. Dostupné online. (korejsky) 

cepi.net

  • CEPI and SK bioscience extend collaboration to develop ‘next generation’ COVID-19 vaccine. CEPI [online]. [cit. 2021-11-16]. Dostupné online. (anglicky) 

clinicaltrials.gov

  • SK BIOSCIENCE CO., LTD. A 2-Stage, Phase I/II, Placebo-controlled, Randomized, Observer-blinded, Dose-finding Study to Assess the Safety, Reactogenicity, and Immunogenicity of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510) Adjuvanted With or Without AS03 in Healthy Younger and Older Adults. [s.l.]: [s.n.] Dostupné online. Submitted: February 10, 2021. 
  • SK BIOSCIENCE CO., LTD. A 2-Stage, Phase I/II, Placebo-controlled, Randomized, Observer-blinded, Dose-finding Study to Assess the Safety, Reactogenicity, and Immunogenicity of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510) Adjuvanted With Aluminum Hydroxide in Healthy Younger and Older Adults. [s.l.]: [s.n.] Dostupné online. Submitted: February 4, 2021. 
  • SK BIOSCIENCE CO., LTD. A Phase III, Randomized, Active-controlled, Observer-blind, Parallel-group, Multi-center Study to Assess the Immunogenicity and Safety of SK SARS-CoV-2 Recombinant Nanoparticle Vaccine Adjuvanted With AS03 (GBP510) in Adults Aged 18 Years and Older. [s.l.]: [s.n.] Dostupné online. Submitted: August 9, 2021. 

skbioscience.co.kr

  • SK bioscience. www.skbioscience.co.kr [online]. [cit. 2021-11-16]. Dostupné online. 

uw.edu

ipd.uw.edu

  • Two nanoparticle vaccines enter clinical trials – Institute for Protein Design [online]. [cit. 2021-11-16]. Dostupné online. (anglicky) 

newsroom.uw.edu

  • CEPI funds Phase 3 trial of UW Medicine COVID-19 vaccine. newsroom.uw.edu [online]. 2021-05-24 [cit. 2021-11-16]. Dostupné online.